Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM) Meeting Abstract
| Authors: | Bahlis, N. J.; Raje, N. S.; Costello, C.; Dholaria, B. R.; Solh, M. M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Liu, F.; Liao, K. H.; Basu, C.; Skoura, A.; Chan, E. M.; Trudel, S.; Jakubowiak, A. J.; Chu, M. P.; Gasparetto, C.; Dalovisio, A.; Sebag, M.; Lesokhin, A. M. |
| Abstract Title: | Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120604169 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.8006 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 8006 -- Source: Wos |
